Department of pathology, faculty of Medicine, Ain Shams university, Cairo, Egypt.
Diagn Pathol. 2014 Mar 25;9:72. doi: 10.1186/1746-1596-9-72.
Defects in Human Leukocyte Antigen (HLA) class I antigen expression and/or function in tumor cells have been extensively investigated, because of their potential role in the escape of tumor cells from T cell recognition and destruction. The researchers evaluated HLA class I expression in tumor tissue as a prognostic factor in osteosarcoma patients and as a predictor of their survival. This retrospective cohort study was conducted at the pathology laboratory of Ain Shams University Hospital, and Ain Shams University Specialized Hospital during the period between January 2009 and January 2012.
The researchers investigated HLA class I expression in primary osteosarcoma by immunohistochemistry using EMR8-5 mAbs. Furthermore, researchers evaluated the correlation between HLA class I expression and the clinicopathological status and outcome in formalin fixed paraffin embedded tissues from thirty six (36) patients with osteosarcoma.
A high expression of HLA class I was detected in 18 (50) % of tumor samples examined; while tumors with low or negative expression represented 9 (25%) cases each. Data indicate that the overall survival rate of patients with tumors highly expressing HLA class I was significantly higher than those with low or negative expression.
Down-regulation of class I antigen expression is associated with features of aggressive disease and a poorer prognosis. Therefore, it is imperative to identify HLA as a prognostic factor at the time of diagnosis to detect chemotherapy-resistant tumors and to generate a modified treatment regimen.
The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1159334857109547.
由于肿瘤细胞中人类白细胞抗原（HLA）I 类抗原表达和/或功能的缺陷可能导致肿瘤细胞逃避 T 细胞识别和破坏，因此人们对其进行了广泛研究。研究人员评估了肿瘤组织中 HLA I 类表达作为骨肉瘤患者的预后因素，并作为其生存的预测指标。本回顾性队列研究在 2009 年 1 月至 2012 年 1 月期间在艾因夏姆斯大学医院和艾因夏姆斯大学专科医院的病理实验室进行。
研究人员通过使用 EMR8-5 mAbs 对原发性骨肉瘤进行免疫组织化学研究，以检测 HLA I 类的表达。此外，研究人员评估了 HLA I 类表达与 36 例骨肉瘤患者福尔马林固定石蜡包埋组织的临床病理状态和结果之间的相关性。
在检查的肿瘤样本中，有 18 例（50%）检测到 HLA I 类高表达；而低表达或阴性表达的肿瘤各有 9 例（25%）。数据表明，HLA I 类高表达的患者总体生存率明显高于低表达或阴性表达的患者。
I 类抗原表达下调与侵袭性疾病和预后不良的特征有关。因此，在诊断时识别 HLA 作为预后因素以检测化疗耐药肿瘤并制定改良的治疗方案至关重要。
本文的虚拟幻灯片可在此处找到：http://www.diagnosticpathology.diagnomx.eu/vs/1159334857109547。
